Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop ...

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

The company is also working toward FDA filings for tolebrutinib in secondary progressive multiple sclerosis and Dupixent for chronic spontaneous urticaria. On Friday, Sanofi was revealed as a new ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod ...

Cardiac complications like arrhythmias, heart failure, and myocardial infarction significantly impact mortality rates in patients with comorbidities. The interaction between cardiac issues and ...

Phase 3 trial results Tolebrutinib (Sanofi) Bruton tyrosine kinase inhibitor Treatment of non-relapsing secondary progressive multiple sclerosis. Phase 3 trial results Depemokimab (GSK) Ultra-long ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...